Skip to content

Septerna, Inc. SEPN Interest Income

Interest Income at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$4.36M+43.1%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$5.32M-18.3%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$8.74M+11.5%
Arrowhead Research logo
Arrowhead ResearchARWR
$16.87M+75.4%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$25.48M+3.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.24M+47.6%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s interest income?
Septerna, Inc. (SEPN) reported interest income of $5.03M in Q1 2026.
How has Septerna, Inc.'s interest income changed year-over-year?
Septerna, Inc.'s interest income increased by 12.8% year-over-year, from $4.46M to $5.03M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.